DK1468008T3 - Polymorphisme af promotoren for migrationshæmmende faktor (MIF) hos makrofager ved inflammationssygdomme - Google Patents

Polymorphisme af promotoren for migrationshæmmende faktor (MIF) hos makrofager ved inflammationssygdomme

Info

Publication number
DK1468008T3
DK1468008T3 DK02798569.6T DK02798569T DK1468008T3 DK 1468008 T3 DK1468008 T3 DK 1468008T3 DK 02798569 T DK02798569 T DK 02798569T DK 1468008 T3 DK1468008 T3 DK 1468008T3
Authority
DK
Denmark
Prior art keywords
mif
polymorphism
macrophages
migration
promoter
Prior art date
Application number
DK02798569.6T
Other languages
English (en)
Inventor
Richard Bucala
John A Baugh
Seamus C Donnelly
Peter K Gregersen
Joanita Monteiro
Smita Chitnis
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Application granted granted Critical
Publication of DK1468008T3 publication Critical patent/DK1468008T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2066IL-10
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/245IL-1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK02798569.6T 2001-12-21 2002-12-23 Polymorphisme af promotoren for migrationshæmmende faktor (MIF) hos makrofager ved inflammationssygdomme DK1468008T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34183201P 2001-12-21 2001-12-21
PCT/US2002/041051 WO2003060468A2 (en) 2001-12-21 2002-12-23 Macrophage migration inhibitory factor (mif) promoter polymorphism in inflammatory disease

Publications (1)

Publication Number Publication Date
DK1468008T3 true DK1468008T3 (da) 2013-07-29

Family

ID=23339212

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02798569.6T DK1468008T3 (da) 2001-12-21 2002-12-23 Polymorphisme af promotoren for migrationshæmmende faktor (MIF) hos makrofager ved inflammationssygdomme

Country Status (10)

Country Link
US (3) US7205107B2 (da)
EP (1) EP1468008B1 (da)
JP (1) JP4625257B2 (da)
AU (1) AU2002364098B2 (da)
CA (1) CA2471513A1 (da)
DK (1) DK1468008T3 (da)
ES (1) ES2423211T3 (da)
PT (1) PT1468008E (da)
SI (1) SI1468008T1 (da)
WO (1) WO2003060468A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1730315T1 (sl) 2004-03-27 2010-02-26 Klein Hanns Georg Polimorfizmi v genu NOD2/CARD15
WO2006116688A2 (en) * 2005-04-26 2006-11-02 Yale University Mif agonists and antagonists and therapeutic uses thereof
US7745121B2 (en) * 2005-05-23 2010-06-29 The Department Of Veterans Affairs Polymorphism in the macrophage migration inhibitory factor (MIF) gene as marker for prostate cancer
US20080089884A1 (en) * 2006-07-06 2008-04-17 Kuchel George A Compositions and methods for the modulation of detrusor activity
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
WO2013050453A1 (en) 2011-10-07 2013-04-11 Baxter Healthcare S.A. Oxmif as a diagnostic marker
AU2013203957B9 (en) * 2012-04-16 2015-10-15 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Glucocorticoids
CN115252636A (zh) * 2022-06-15 2022-11-01 南方医科大学顺德医院(佛山市顺德区第一人民医院) 一种寡聚脱氧核苷酸及其在制备抗肿瘤药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645493B1 (en) 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody

Also Published As

Publication number Publication date
EP1468008A4 (en) 2005-02-02
US7205107B2 (en) 2007-04-17
SI1468008T1 (sl) 2013-08-30
US20160201130A1 (en) 2016-07-14
JP4625257B2 (ja) 2011-02-02
WO2003060468A2 (en) 2003-07-24
AU2002364098A1 (en) 2003-07-30
WO2003060468A3 (en) 2003-12-04
AU2002364098B2 (en) 2009-03-19
PT1468008E (pt) 2013-07-31
US20130189678A1 (en) 2013-07-25
US9139877B2 (en) 2015-09-22
ES2423211T3 (es) 2013-09-18
EP1468008B1 (en) 2013-05-01
CA2471513A1 (en) 2003-07-24
US20030215446A1 (en) 2003-11-20
EP1468008A2 (en) 2004-10-20
JP2005514932A (ja) 2005-05-26

Similar Documents

Publication Publication Date Title
DE60207390D1 (de) Entzündungshemmende benzimidazolverbindungen
DE60234939D1 (de) Stent für die eustachische röhre
DE60214480D1 (de) Plasma Anzeigetafel
DE60215275D1 (de) Fahrradscheibenbremsnabe
DE60225526D1 (de) Polyesterfolie für Trennfolie
DE60232179D1 (de) Folienverbund
DE60000327T2 (de) Beschaltung für leistungsfaktorkorrektur
DE60201470D1 (de) Fahrradscheibenbremsnabe
FI20010922A0 (fi) Uusia vektoreita
DK1468008T3 (da) Polymorphisme af promotoren for migrationshæmmende faktor (MIF) hos makrofager ved inflammationssygdomme
DE60200791D1 (de) Mehrschichtfolie
DE60216015D1 (de) Aussenbordmotor
FI20011507A0 (fi) Uusia yhdisteitä
FI20020258A (fi) Kiristyselin
FI20031042A0 (fi) Puristusmekanismi
DE60104482D1 (de) Okklusionskatheter für der Aufsteigenden Aorta
NO20001134D0 (no) FremgangsmÕte for fremstilling av VCM
DE60304263D1 (de) Fahrzeugpedal-Stützkonstruktion
FI20021783A0 (fi) Menetelmä kardiovaskulaaristen sairauksien riskin havaitsemiseksi
ITMI20021358A0 (it) Catalizzatore per la preparazione di anidride ftalica
DE50200573D1 (de) Prepreg
DE50206876D1 (de) Titan-Zirkonium-Legierung
FR2863143B3 (fr) Releveur d'epis
DE60226753D1 (de) Neues amidhydrolasegen
NO20043935L (no) Fremgangsmåte ved fremstilling av interferon